Abstract 1279
Background
The newly created Department of Oncology Nurse Coordinators, in this case the Digestive Oncology department, ONCDOD, at the Jules Bordet Institute, allows patients, mainly the newly diagnosed, to early personalized medicine. The aim is to orient the patients to all the services available and implicated to his/her care; to explain the treatment, procedures for therapies and answer questions; to be present for the patient and his family so as to create a climate of confidence, comfort and security.
Methods
60 newly diagnosed digestive patients were followed by the Nurse Coordinator in the year 2018. The necessary care requirements for this group of patients were identified, recorded and analysed in collaboration with the multidisciplinary team. With the help of an exhaustive data on the patient, all the Oncology Nurse Coordinator’s activities were reported in a unique, accessible electronic patient’s file.
Results
Thanks to knowledge of the patient’s medical situation, but also to his psychological and socioeconomic environment, the interventions of the Oncology Nurse Coordinator allowed a more fluid path of diagnosis and treatment, rapid and efficient care of treatment side effects, avoid unnecessary hospitalization and ensure more comfort and security for the patient.
Conclusions
The daily follow-up of newly diagnosed digestive patients, allowed a more effective taking care of patients from the diagnosis. The patients showed confidence and serenity knowing that they can call one single person, anytime, in the hospital for all their questions and needs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Fouad Awada.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
5056 - Phase 2 study of 2 dosing regimens of cemiplimab, a human monoclonal anti–PD-1, in metastatic cutaneous squamous cell carcinoma (mCSCC)
Presenter: Danny Rischin
Session: Poster Display session 3
Resources:
Abstract
5710 - Avelumab for advanced Merkel cell carcinoma in the Netherlands; a nationwide survey
Presenter: Sonja Levy
Session: Poster Display session 3
Resources:
Abstract
3152 - Health-related quality of life in patients with metastatic Merkel cell carcinoma receiving second-line or later avelumab treatment: 36-month follow-up data
Presenter: Sandra D'Angelo
Session: Poster Display session 3
Resources:
Abstract
5715 - A Phase 2, Randomized Study of Nivolumab (NIVO) and Ipilimumab (IPI) versus NIVO, IPI and Stereotactic Body Radiation Therapy (SBRT) for Metastatic Merkel Cell Carcinoma (MCC, NCT03071406) – a preliminary report.
Presenter: Sungjune Kim
Session: Poster Display session 3
Resources:
Abstract
2854 - Real-world impact of immune checkpoint inhibitors in metastatic uveal melanoma
Presenter: Kalijn Bol
Session: Poster Display session 3
Resources:
Abstract
2928 - Immune checkpoint inhibitors in a cohort of 206 metastatic uveal melanomas patients
Presenter: Mathilde Saint-Ghislain
Session: Poster Display session 3
Resources:
Abstract
1235 - Incidence and survival of Uveal Melanoma occurring as single cancer versus its occurrence as a first or second primary neoplasm
Presenter: Ahmad Alfaar
Session: Poster Display session 3
Resources:
Abstract
3615 - Validation of a Clinicopathological and Gene Expression Profile (CP-GEP) Model for Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma
Presenter: Evalyn Mulder
Session: Poster Display session 3
Resources:
Abstract
1793 - External validation of the 8th Edition Melanoma Staging System of the American Joint Committee on Cancer (AJCC) using the Surveillance, Epidemiology and End Results (SEER) Program
Presenter: Angelina Tjokrowidjaja
Session: Poster Display session 3
Resources:
Abstract
4278 - Clinical factors and overall survival (OS) associated with patterns of metastases (mets) in melanoma patients (pts).
Presenter: Ines Pires da Silva
Session: Poster Display session 3
Resources:
Abstract